Skip to content

Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

Comparing the Efficacy of VL-UVA1 Versus NB-UVB on Inducing Repigmentation in Subjects With Generalized Vitiligo

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05238077
Enrollment
1
Registered
2022-02-14
Start date
2018-02-26
Completion date
2020-06-02
Last updated
2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Vitiligo

Brief summary

As part of this study, you may have a procedure called phototherapy which involves either VL-UVA or NB-UVB irradiation. NB-UVB phototherapy is not experimental in vitiligo, but use of VL-UVA1 phototherapy in vitiligo is. The purpose of this pilot study is to determine whether VL-UVA1 or NB-UVB phototherapy more efficiently induces repigmentation in patients with generalized vitiligo.

Interventions

PROCEDUREVisible Light-Ultraviolet A Light or Narrowband-Ultraviolet B phototherapy

Patients will have different kinds of light shined on different areas

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The subject serves as their own control.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects ≥ 18 years of age with a diagnosis of generalized vitiligo * Subjects on a stable topical/oral regimen for the past 3 months and continuing on a stable regimen * Subjects able to understand the requirements of the study * Subjects able and willing to sign informed consent

Exclusion criteria

* Subjects on photosensitizing medications * Subjects receiving any concurrent phototherapy * Subjects who plan to use tanning parlors or expose themselves to excess sunlight * Subjects with known photosensitivity disorder * Subjects with apparent phototoxicity * Subjects with unstable vitiligo * Subjects currently using bleaching agents * Subjects who are pregnant, lactating, or planning on becoming pregnant * Subjects who in the opinion of the investigator/sub-investigator, are not appropriate candidates for this study

Design outcomes

Primary

MeasureTime frameDescription
Change in depigmentation of vitiligo lesion13 measurements over 26 visitsChange in pigment will be assessed by colorimetry which measures change in pigment
Change in melanin content of vitiligo lesion13 measurements over 26 visitsChange in pigment will be assessed by diffuse reflectance spectroscopy which will measure the melanin content and dyschromia

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026